# Atea Pharmaceuticals, Inc. (AVIR) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Atea Pharmaceuticals, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AVIR/mda/fy2025/): filed 2026-03-05; accession 0001193125-26-094159 (https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/AVIR/mda/fy2024/): filed 2025-03-06; accession 0000950170-25-034808 (https://www.sec.gov/Archives/edgar/data/1593899/000095017025034808/avir-20241231.htm)
- [FY 2023 MD&A](/company/AVIR/mda/fy2023/): filed 2024-02-28; accession 0000950170-24-022226 (https://www.sec.gov/Archives/edgar/data/1593899/000095017024022226/avir-20231231.htm)
- [FY 2022 MD&A](/company/AVIR/mda/fy2022/): filed 2023-02-28; accession 0000950170-23-005186 (https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/avir-20221231.htm)
- [FY 2021 MD&A](/company/AVIR/mda/fy2021/): filed 2022-02-28; accession 0001564590-22-007672 (https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-10k_20211231.htm)

Back to /company/AVIR/